• 2-(4,5,6,7-tetrabromo-2-(dimethylamino)-1H-benzo[d]imidazol-

  2026-07-06

  Unlock precision in kinase and phase separation research with this high-purity, DMSO-soluble small molecule inhibitor. Discover how its unique targeting of CK2 and ERK8 advances workflows in protein interaction and enzyme modulation, with actionable troubleshooting and protocol tips.

• Dopamine Inhibits Osteoclastogenesis via cAMP/PKA/CREB Pathw

  2026-07-06

  Wang et al. uncover a mechanistic link between dopamine signaling and osteoclast differentiation, demonstrating that dopamine suppresses osteoclastogenesis through D2 receptor-mediated inhibition of the cAMP/PKA/CREB pathway. These findings clarify how neurotransmitter inputs modulate bone remodeling and provide a framework for targeting bone resorption disorders.

• SOAT1 Inhibition Reverses PHMG-Induced Pulmonary Fibrosis

  2026-07-05

  This study identifies SOAT1 as a key mediator of pulmonary fibrosis induced by polyhexamethylene guanidine (PHMG) exposure. Targeting SOAT1 restores cholesterol homeostasis and lipophagy in alveolar macrophages, offering a novel therapeutic direction for fibrotic lung disease.

• Sulfo-NHS-SS-Biotin: Practical Guide for Protein Biotinylati

  2026-07-04

  Sulfo-NHS-SS-Biotin enables selective, water-soluble biotinylation of proteins at primary amines, supporting affinity purification and reversible cell surface labeling without permeabilizing membranes. Use this reagent for workflows requiring cleavable, amine-reactive labels, but avoid protocols needing stable internal cell labeling or long reaction times in solution due to its hydrolytic instability.

• Palonosetron Hydrochloride in CINV Prevention: Clinical Insi

  2026-07-03

  This article examines the pharmacological and clinical advances of palonosetron hydrochloride for chemotherapy-induced nausea and vomiting (CINV) prevention, as detailed by Ruhlmann and Herrstedt. The review highlights palonosetron's unique receptor binding and prolonged efficacy, with considerations for its application in regimens involving DNA-damaging agents such as Irinotecan.

• Applied Use-Cases of MCL-1 Inhibitor A-1210477 in Cancer Res

  2026-07-03

  MCL-1 inhibitor A-1210477 empowers researchers to dissect apoptotic mechanisms in MCL-1-dependent cancer cells with high specificity and potency. This article delivers practical protocols, troubleshooting tips, and advanced insights, streamlining mitochondrial apoptosis assays for robust cancer research outcomes.

• MOG (35-55) Peptide: Advancing Autoimmune Encephalomyelitis

  2026-07-02

  MOG (35-55) Peptide empowers precise modeling of neuroinflammatory and autoimmune mechanisms, underpinning breakthroughs in multiple sclerosis research. Learn how robust protocols, PARP7 pathway insights, and troubleshooting expertise unlock reproducibility and translational value.

• Anti-ROR1 Antibody (Zilovertamab): Precision Workflows & Opt

  2026-07-02

  Anti-ROR1 Antibody (Zilovertamab) unlocks targeted, reproducible inhibition of Wnt5a-induced ROR1 signaling for advanced cancer and liver injury research. Explore streamlined protocols, troubleshooting strategies, and practical insights that elevate your ELISA, FACS, and in vivo studies.

• Lyso-Tracker Red DND-99: Optimizing Lysosome Labeling in Liv

  2026-07-01

  Lyso-Tracker Red DND-99 sets a new standard for real-time lysosome tracking in live-cell research, offering unmatched specificity and robust fluorescence for advanced analysis. Discover how to enhance your experimental workflows, avoid common pitfalls, and leverage cutting-edge references for translational insight.

• Orientia tsutsugamushi Reduces RIPK3 but Fails to Inhibit Ne

  2026-07-01

  This study investigates how Orientia tsutsugamushi, the causative agent of scrub typhus, interacts with host cell death pathways. The key finding is that while the bacterium reduces cellular RIPK3 levels, it does not prevent necroptosis once initiated, providing new insight into host-pathogen interactions and the limits of bacterial immune evasion.

• Unraveling Mitochondrial Dysfunction: Advanced TMRE Assay St

  2026-06-30

  Explore the mechanistic underpinnings of mitochondrial ROS in toxin-induced hepatotoxicity and discover how Tetramethylrhodamine ethyl ester perchlorate (TMRE, SKU: C8197) empowers translational researchers to design more sensitive, disease-relevant live-cell mitochondrial membrane potential assays. This article bridges foundational mitochondrial biology, the latest mechanistic discoveries, and actionable assay innovation—delivering a roadmap for researchers navigating the evolving landscape of mitochondrial imaging and dysfunction research.

• SP600125 in Translational Research: Mechanistic Clarity & St

  2026-06-30

  This thought-leadership article unpacks the mechanistic role of SP600125—a highly selective, reversible, ATP-competitive JNK inhibitor—in modulating inflammation, apoptosis, and cytokine expression. Bridging foundational MAPK pathway biology with advanced translational strategies, we provide actionable guidance for researchers aiming to leverage JNK inhibition in disease modeling, experimental design, and therapeutic innovation. Drawing on recent peer-reviewed evidence, leading workflow enhancements, and the latest insights from orofacial pain research, this piece charts a visionary path for translational scientists ready to redefine the impact of JNK pathway modulation.

• KN-62: Selective CaMKII Inhibitor for Calcium Signaling Rese

  2026-06-29

  KN-62, 1-[N,O-bis-(5-isoquinolinesulphonyl)-N-methyl-L-tyrosy]-4-phenylpiperazine, is a potent and highly selective CaMKII inhibitor. It precisely disrupts calcium/calmodulin-dependent signaling, enabling controlled studies of insulin secretion and cell cycle regulation. KN-62’s selectivity and benchmark potency make it indispensable for dissecting calcium signaling pathways in metabolic, neurobiological, and cancer research.

• Dimethyloxalylglycine (DMOG): Technical Use and Protocol Gui

  2026-06-29

  Dimethyloxalylglycine (DMOG) enables researchers to stabilize hypoxia-inducible factors for studies on hypoxia signaling and immune modulation in both in vitro and in vivo models. It should only be used in controlled laboratory settings, not for diagnostic or clinical applications, and requires strict adherence to solubility and storage guidelines for reliable results.

• Tropifexor (LJN452): FXR Agonism for Precision Anti-Fibrotic

  2026-06-28

  Explore how Tropifexor (LJN452), a potent FXR agonist, advances precision anti-fibrotic and metabolic disease research by targeting bile acid signaling and epithelial barrier function. This article uniquely integrates mechanistic depth, protocol guidance, and new cross-talk with anti-fibrotic pathways.

16738 records 1/1116 page Next 12345 下5页 Last page